The latest research study “Liquid Biopsy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” by IMARC Group, finds that the global liquid biopsy market share reached a value of US$ 1.49 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 3.7 Billion by 2027 exhibiting a CAGR of 15.70% during 2022-2027.
Request a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/liquid-biopsy-market/requestsample
Liquid biopsy refers to a non-invasive alternative to surgical biopsies enabling doctors to obtain information about a tumor via a blood sample and plan the treatment accordingly. It offers a robust base for individualized therapy and can reflect changes in tumor gene expression profile. Liquid biopsy aids in the early diagnosis screening, tumor heterogeneity, drug resistance, etc. In addition to this, it detects epidermal growth factor receptor (EGFR) gene mutations, which occur among patients with non-small cell lung cancer (NSCLC). Consequently, liquid biopsy is extensively utilized in academic and research centers, hospitals, laboratories, etc.
COVID-19Impact on Market: As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviors of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
Liquid Biopsy Market Trends and Drivers:
The increasing consumer awareness towards advanced minimally invasive (MI) procedures in cancer diagnostics is primarily driving the liquid biopsy market. Besides this, government bodies are investing in R&D activities to encourage the introduction of advanced cancer solutions, which is further catalyzing the market growth.
Moreover, leading manufacturers are focusing on developing personalized medicine and integrating technological advancements in liquid biopsy to offer better procedure workflow as well as output. This, in turn, is also propelling the demand for liquid biopsy. Additionally, the widespread adoption of exosomes for clinical diagnosis in oncology to provide high accuracy and reduced procedural time is acting as another significant growth-inducing factor.
Apart from this, numerous advancements in digital polymerase chain reaction (PCR) and next-generation sequencing (NGS) based technology are anticipated to fuel the liquid biopsy market over the forecasted period.
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/liquid-biopsy-market
|Liquid Biopsy Market Report Scope|
|Market size value in 2021||US$ 1.49 Billion|
|Market forecast in 2027||US$ 3.7 Billion|
|Growth Rate||CAGR of 15.70% from 2022 to 2027|
|Base year for estimation||2021|
Global Liquid Biopsy Market 2022-2027 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
ANGLE plc, Biocept Inc., Bio-Rad Laboratories Inc, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Guardant Health Inc., Illumina Inc., MDxHealth SA, Menarini Silicon Biosystems, QIAGEN N.V. and Thermo Fisher Scientific Inc.
The report has segmented the market on the basis of region, product and service, circulating biomarker, cancer type and end user.
Breakup by Product and Service:
- Kits and Reagents
- Platforms and Instruments
Breakup by Circulating Biomarker:
- Circulating Tumor Cells
- Extracellular Vesicles
- Circulating Tumor DNA
Market Breakup by Cancer Type:
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Liver Cancer
Breakup by End User:
- Hospitals and Laboratories
- Academic and Research Centers
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022- 2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800